In regards to the clinical significance of HSP90 in ErbB2-mediated breast cancer, targeting HSP90 is emerging as a novel therapeutic strategy to destabilize and degrade its client proteins, particularly ErbB2. The gene discussed is ERBB2; the disease is breast carcinoma.